Search

 
 
 
 
 
 
Neural Mutations at Mid-gestation Can Mean Health Issues Years Later

NEURAL MUTATIONS AT MID-GESTATION CAN MEAN HEALTH ISSUES YEARS LATER

Mayo Clinic researchers, along with colleagues from Yale, Stanford and the New York Genome Center, have published findings that show...

 
 
 
Man flu does exist and the caveman are to blame!

MAN FLU DOES EXIST AND THE CAVEMAN ARE TO BLAME!

The evidence is presented in the British Medical Journal , in a report by Dr Kyle Sue, a clinical assistant professor at Memorial University...

Antidepressants and Bone Health

ANTIDEPRESSANTS AND BONE HEALTH

For patients with depression , genetic testing may offer more than just medication guidance. In a new paper , Mayo researchers link...

 
 
 
Smell Test Challenge Suggests Clinical Benefit for Some Before Development of Alzheimer's

SMELL TEST CHALLENGE SUGGESTS CLINICAL BENEFIT FOR SOME BEFORE DEVELOPMENT OF ALZHEIMER'S

Researchers may have found a way to prevent the effects of Alzheimer's using a person's sense of smell. It has been determined that...

ALZHEIMER'S GRANT

Three physician-scientists, including a top San Diego-based Alzheimer's researcher, will get up to $70 million to accelerate clinical...

 
 
 

RECRUITING MANAGER

Tocagen is a clinical-stage, cancer-selective gene therapy company focused on developing first-in-class, broadly applicable product...

Alzheimer's treatment may need to begin before plaques form

ALZHEIMER'S TREATMENT MAY NEED TO BEGIN BEFORE PLAQUES FORM

One of the defining characteristics of Alzheimer's disease is the presence of toxic amyloid plaques that build up in patients' brains....

 
 
 
New Biomarkers May Speed Clinical Trials of ALS Drugs

NEW BIOMARKERS MAY SPEED CLINICAL TRIALS OF ALS DRUGS

Just over five years ago, the lab of neurogeneticist Rosa Rademakers, Ph.D. , on Mayo Clinic's campus in Florida , discovered a genetic...

 
 
 
Revance Botulinum Toxin Achieves Six-Month Duration in Phase 3 Trials

REVANCE BOTULINUM TOXIN ACHIEVES SIX-MONTH DURATION IN PHASE 3 TRIALS

Revance Therapeutics' DaxibotulinumtoxinA for Injection achieved six-month duration in two pivotal SAKURA Phase 3 clinical studies...

UnitedHealth ventures deeper into care with nearly $5B deal

UNITEDHEALTH VENTURES DEEPER INTO CARE WITH NEARLY $5B DEAL

The nation's biggest health insurer is spending nearly $5 billion to buy hundreds of clinics, just three days after rival Aetna announced...

 
 
 
 
 
 
Initial Findings of the Human Vaccine Project from Its First Clinical Trials

INITIAL FINDINGS OF THE HUMAN VACCINE PROJECT FROM ITS FIRST CLINICAL TRIALS

Based on the initial findings from the first clinical trials of the human genome project,two concurrent clinical studies were reported.

NEUROCRINE BIOSCIENCES PRESENTS LONG-TERM DATA ANALYSES FROM OPEN-LABEL KINECT 4 PHASE III STUDY DEMONSTRATING INGREZZA® IMPROVES TARDIVE DYSKINESIA SYMPTOMS

INGREZZA Capsules Taken Once-daily Improved Tardive Dyskinesia Symptoms in Patients and was Generally Well Tolerated in 52-week Trial-...